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Antibiotic resistance, particularly to carbapenems, is of increasing concern in
Bacteroides fragilis. Carbapenem resistance in B. fragilis is most often mediated by the activation of chromosomally encoded metallo-b -lactamase cﬁA by the presence of an upstream
insertion sequence (IS). While traditional phenotypic susceptibility methods and molecular
tests to detect carbapenem resistance in B. fragilis exist, they are not available in most clinical microbiology laboratory settings. Here, we describe the development of the anaerobic
carbapenem inactivation method (Ana-CIM) for predicting carbapenemase production in B.
fragilis based off the principles of the well-established modiﬁed carbapenem inactivation
method (mCIM) for Enterobacterales and Pseudomonas aeruginosa. We also present the clinical validation and reproducibility of the Ana-CIM at three clinical laboratory sites (with 60
clinical isolates, 45% ertapenem resistant). Compared to ertapenem susceptibility by Etest
interpreted by CLSI M100 Ed30, the Ana-CIM accurately detected carbapenem resistance in
B. fragilis with categorical agreement (CA) of 87% (52/60) and 0% (0/21) very major error
(VME), 11% (4/36) major error (ME), and 7% (4/60) minor error (mE) rates across all sites.
Additionally, the Ana-CIM demonstrated high reproducibility with 5 clinical and 3 quality
control (QC) isolates tested in triplicate with 3 commercial Mueller-Hinton media across all
sites, with 93% (604/648) of replicates within a 2-mm zone size of the mode for each isolate. We conclude that the Ana-CIM can be readily deployed in clinical laboratories at a low
cost for detection of carbapenemase-mediated resistance in B. fragilis.
KEYWORDS Bacteroides fragilis, anaerobes, antimicrobial susceptibility testing,

carbapenem resistance, carbapenemase production
Editor Patricia J. Simner, Johns Hopkins

A

naerobic infections are associated with signiﬁcant morbidity and mortality. Bacteroides
species are among the most common and virulent agents of anaerobic infections,
largely attributed to high levels of antimicrobial resistance that have been shown to contribute to poor outcomes (1). Most Bacteroides species are resistant to penicillin and ampicillin and have variable susceptibility to cephalosporins due to the activity of chromosomally
encoded b -lactamase cepA, which hydrolyzes cephalosporins and aminopenicillins, and
cfxA, which hydrolyzes cefoxitin and other b -lactams (2).
Carbapenem antibiotics remain an effective therapeutic option for multidrug-resistant (MDR) Bacteroides species, with most isolates testing susceptible (3). However, recent
national and international surveys have found increasing rates of carbapenem resistance,
nearly doubling from 0.5 to 1.6% carbapenem intermediate/resistant in 2006 to 2007 to
1.1 to 2.4% in 2010 to 2012 in the United States (3, 4) and up to 3.4% and 2.4% in Europe
and South America, respectively (5, 6). In Bacteroides fragilis, most of the carbapenem
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resistance is mediated by chromosomally encoded metallo-b -lactamase cﬁA, which normally
exhibits low-level expression that is increased in the presence of insertion sequences (IS),
upstream of the cﬁA promoter (7). Conversion of cﬁA-positive B. fragilis isolates from carbapenem susceptible to carbapenem resistant has been previously demonstrated during carbapenem therapy (7). Identiﬁcation and differentiation of carbapenemase-producing B. fragilis
isolates from nonenzymatic mechanisms of carbapenem resistance are important for evaluating the therapeutic potential of carbapenem therapy, as carbapenemase-producing isolates
will likely be resistant to all carbapenems (6). Due to diversity in sequence and location of IS
elements, PCR-based tests have limited sensitivity for detection of cﬁA-mediated carbapenem
resistance and are not practical to implement in the workﬂow in most clinical microbiology
laboratories. Phenotype-based tests including double-ended Etest strip with or without EDTA,
double disk diffusion, and detection of enzymatic activity via colorimetric assay (e.g., CarbaNP), as well as the molecular biology-based matrix-assisted laser desorption ionization–time of
ﬂight mass spectrometry (MALDI-ToF MS), have been approved for aerobes but have not
been widely evaluated or implemented by clinical laboratories for anaerobic microorganisms
(8–10). Phenotypic susceptibility test methods for anaerobes such as agar dilution and gradient diffusion strips require $24 h after assay setup to yield results; however, the availability of
this testing is often delayed as most clinical laboratories do not perform this testing and must
send out isolates to a reference laboratory.
Our goal was to develop and evaluate a novel assay, the Anaerobic Carbapenem
Inactivation Method (Ana-CIM), for the detection of carbapenemase production in B. fragilis.
The Ana-CIM assay is a simple methodology derived from the principles of the modiﬁed carbapenem inactivation method (mCIM) for Enterobacterales and Pseudomonas aeruginosa and
utilizes materials readily available in clinical laboratories capable of isolating anaerobic bacteria
(11). This study was established with B. fragilis sensu stricto isolates only, as carbapenemase
production has not been characterized in other non-fragilis Bacteroides species. After initial
method development and optimization, we performed a pilot study at three study sites, followed by a multicenter validation study and reproducibility study (Fig. 1). We report that the
Ana-CIM reproducibly detects carbapenemase production in B. fragilis isolates with high agreement to phenotypic and predicted genomic carbapenem susceptibility. The Ana-CIM can be
readily implemented and can provide information about carbapenemase production
results about a day faster than conventional susceptibility results for B. fragilis isolates from
sterile body sites or when carbapenem resistance is suspected.
MATERIALS AND METHODS
Clinical isolates. Sixty deidentiﬁed clinical isolates of B. fragilis were obtained from Washington
University School of Medicine (WU), St. Louis, MO; Mayo Clinic (MC), Rochester, MN; and Nationwide Children’s
Hospital (NCH), Columbus, OH (n = 27, 22, and 11 isolates, respectively). Isolates were recovered from various
specimen types including abscesses, blood, body ﬂuids, and wounds and were identiﬁed by MALDI-ToF MS
(see Table S1 in the supplemental material). All isolates were transferred to WU, where antimicrobial susceptibility testing (AST) for ertapenem and meropenem was performed by Etest (bioMérieux, Durham, NC) before
isolates were coded and returned to each site for Ana-CIM testing.
Molecular detection of carbapenemase genetic determinants. All isolates were subjected to endpoint PCR to detect cﬁA and upstream IS elements as previously described (12). Prediction of CﬁA by
Bruker Biotyper was evaluated as previously described (12).
Anaerobic susceptibility testing. All isolates were tested for susceptibility to ertapenem and meropenem initially by Etest at WU and subsequently by agar dilution at MC. For the Etest, a 1 McFarland standard
suspension of 24- to 48-h growth on prereduced anaerobically sterile (PRAS) Brucella blood agar with hemin
and vitamin K (H1K) (Hardy Diagnostics, Santa Maria, CA) in Brucella broth (BD BBL, Sparks, MD) was used to
inoculate PRAS Brucella blood H1K agar plates. Etest strips were placed on lawn-struck plates and incubated
at 35°C in AnaeroGen 2.5-L atmosphere generating systems (Oxoid, Ltd.) for up to 72 h. MICs were read and
recorded at 72 h. Agar dilution testing of ertapenem and meropenem was performed as described in the Clinical
and Laboratory Standards Institute (CLSI) document M11-A9 at MC (13). Interpretive criteria were applied according to the CLSI M100 Ed30 document (14) and EUCAST 2020 guidelines (15).
Anaerobic carbapenem inactivation method (Ana-CIM). Please refer to supplementary ﬁle 1 in the
supplemental material for the detailed development of Ana-CIM methods. B. fragilis isolates were subcultured for
isolation to prereduced Brucella blood agar with hemin and vitamin K (Hardy Diagnostics, Santa Maria, CA). To
maintain selective pressure, a 10-m g meropenem disk was placed in the ﬁrst quadrant of each plate. Plates were
incubated at 35°C in an anaerobic atmosphere for 24 to 48 h. Following incubation, a new 10-m g meropenem
disk was placed into a 5-mL tube of Brucella broth (BD BBL, Sparks, MD) and incubated at room temperature for
15 min to distribute antibiotic (without introducing excess oxygen by vortexing or inverting the tubes). Growth
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FIG 1 Overview of study workﬂow. After initial assay development at WU, a pilot study collection
containing 20 isolates of B. fragilis from WU was tested by three clinical laboratories to evaluate the
assay protocol. Quality control (QC) isolates were tested at all sites at least daily. Next, for the clinical
validation study, 35 clinical isolates originating from all three sites were tested by the Ana-CIM at all
sites. Finally, a reproducibility study was performed on a total of eight (ﬁve test and three QC)
isolates. These eight isolates were tested in triplicate on three different days with three different
media by all three sites for a total of 81 replicates per isolate. Abbreviations: Ana-CIM, anaerobic
carbapenem inactivation method; MC, Mayo Clinic; NCH, Nationwide Children’s Hospital; QC, quality
control; WU, Washington University School of Medicine.
of each isolate from solid medium closest to the meropenem disk was taken and suspended in the Brucella broth
containing the meropenem disk to obtain a 1 McFarland standard suspension. The ﬁnal suspensions were incubated anaerobically at 35°C for 6 h.
After incubation, using a sterile 10-m L loop, meropenem disks were removed from Brucella broth tubes
and placed on a 15- by 150-mm Mueller-Hinton (MH) plate (Hardy Diagnostics, Santa Maria, CA) inoculated
with a conﬂuent lawn of a 0.5 McFarland standard suspension of Escherichia coli ATCC 25922. A maximum of 8
disks was placed on one plate (5 test isolates and 3 quality control [QC] organisms). MH plates were incubated
for 18 h at 35°C in an air incubator. Zone sizes around each meropenem disk were measured using reﬂected
light and recorded using a metric ruler. Ana-CIM results were interpreted according to both CLSI M100 Ed30
mCIM interpretive criteria for Enterobacterales and interpretive criteria developed in our pilot study (Table 1).
In keeping with the CLSI guidance on mCIMs, microcolonies or colonies inside the zone of inhibition were read
and measured as growth (Fig. 2).
QC was performed every day of Ana-CIM testing, such that out of the 8 disks on the test plate, 3
were QC isolates. Two positive-control isolates were utilized to control for carbapenem inactivation and
adequate anaerobiosis, respectively: (i) Klebsiella pneumoniae ATCC BAA-1705, a K. pneumoniae carbapenemase
(KPC) producer that is utilized as the mCIM positive control recommended by CLSI, and (ii) B. fragilis WIS-ImiR-

TABLE 1 CLSI mCIM interpretive criteria and lab-developed Ana-CIM interpretive criteria
Result
Positive
Negative
Indeterminate
aPer

CLSI mCIMa (zone size, mm)
#15
$19
16–18

Ana-CIM (zone size, mm)
#8
$15
9–14

CLSI M100 Ed30 for Enterobacterales.

April 2022 Volume 60 Issue 4

10.1128/jcm.02188-21

3

Downloaded from https://journals.asm.org/journal/jcm on 07 June 2022 by 128.252.174.220.

Ana-CIM for B. fragilis

Ana-CIM for B. fragilis

Journal of Clinical Microbiology

001, a carbapenem-resistant (ertapenem, imipenem, and meropenem MICs of $32 m g/mL) isolate that tested
positive for cﬁA and upstream IS by previously described PCR (16). Both positive-control isolates have mCIM/
Ana-CIM results of #8 mm. B. fragilis ATCC 25285 served as the negative QC strain, with an expected Ana-CIM
result of $15 mm.
Anaerobic incubation. For anaerobic conditions, WU and NCH used the AnaeroGen 2.5-L atmosphere generating systems (Oxoid, Ltd.) for all studies. MC utilized the Coy Laboratory Products Inc. anaerobic
chamber with a gas mixture of 90% nitrogen, 5% carbon dioxide, and 5% hydrogen (Praxair Inc.). Anaerobic
indicators were included with all testing to ensure an anaerobic environment had been achieved.
Pilot study. Twenty isolates originating from WU were tested at each site for proof of concept and
to reﬁne lab-developed Ana-CIM interpretive criteria. At this time, each site performed testing at the respective institution using the described Ana-CIM procedure. Each institution used the same brands of
solid media (Brucella blood H1K and MH agar; Hardy Diagnostics), broth (Brucella broth; BD BBL), and
meropenem disks (BD BBL) for testing.
Clinical isolate validation study. Thirty-ﬁve isolates, representing strains recovered in clinical specimens from all three institutions (WU, n = 6; MC, n = 20; and NCH n = 9), were tested using the Ana-CIM
procedure using the same conditions described for the pilot study testing.
Reproducibility study. Reproducibility testing consisted of ﬁve clinical isolates (WU, n = 1; MC,
n = 2; and NCH, n = 2) and the three QC isolates previously described. Each isolate was tested in triplicate, on three different days, using three different brands of MH plates (Hardy Diagnostics [Santa Maria,
CA], BD Biosciences [San Jose, CA], and Remel [Lenexa, KS]). All sites used the same lot number and expiration date of all three MH brands. Due to supply shortages during the COVID-19 pandemic, only WU
was able to perform testing using commercially prepared Brucella broth as described in the Ana-CIM
procedure and used for the pilot and clinical validation study. NCH and MC used the same lot of dehydrated Brucella broth (BD BBL, Sparks, MD) resuspended per manufacturer’s instructions and dispensed
into 5-mL tubes prior to sterilization for testing.
All pilot, clinical, and reproducibility study isolates tested are listed with isolate source, site of origin,
phenotypic carbapenem susceptibility, and genotypic carbapenemase results (see Table S1 in the supplemental material).
Data analysis. Ana-CIM testing was compared to ertapenem Etest as the reference method and
interpreted using CLSI M100 Ed30 (Table 2). Ertapenem was used as the reference for phenotypic susceptibility
based on previous reports of higher mean MICs for ertapenem than for meropenem in B. fragilis with the rationale that this would result in a more conservative assessment of Ana-CIM performance (3, 17). Categorical agreement (CA) was deﬁned as the percentage of total Ana-CIM test results in agreement with expected results from
traditional phenotypic susceptibility testing. For the pilot, clinical, and reproducibility studies utilizing the AnaCIM, the minor error (mE) rate was deﬁned as the percentage of total isolates for which the ertapenem Etest with
CLSI interpretation was resistant or susceptible but the Ana-CIM result was indeterminate or when the Etest result
was intermediate and the Ana-CIM was either positive or negative. The major error (ME) was deﬁned as the percentage of isolates susceptible by Etest but interpreted as positive (i.e., resistant) by the Ana-CIM. The very major
error (VME) was deﬁned as the percentage of isolates testing ertapenem resistant by Etest that tested Ana-CIM
negative (i.e. susceptible). For the reproducibility studies, the range and mode of millimeter zone sizes were calculated for all replicates per site and MH agar brand, as well as across all replicates (see Table 4 and 5).

TABLE 2 Overall performance of Ana-CIM compared to ertapenem Etest susceptibility using CLSI and EUCAST breakpointsa
EUCAST (15)

CLSI (14)
Study
Pilot

Comparator
mCIM
Ana-CIM

CA
95% (19/20)
95% (19/20)

VME
0% (0/8)
0% (0/8)

ME
0% (0/12)
0% (0/12)

mE
5% (1/20)
5% (1/20)

CA
95% (19/20)
95% (19/20)

VME
0% (0/8)
0% (0/8)

ME
0% (0/12)
0% (0/12)

mE
5% (1/20)
5% (1/20)

Clinical

Ana-CIM

86% (30/35)

0% (0/12)

10% (2/20)

9% (3/35)

94% (33/35)

17% (2/12)

0% (0/20)

0% (0/35)

Repro

Ana-CIM

60% (3/5)

0% (0/1)

50% (2/4)

0% (0/5)

100% (5/5)

0% (0/3)

0% (0/2)

0% (0/5)

Overall

Ana-CIM

87% (52/60)

0% (0/21)

11% (4/36)

7% (4/60)

95% (57/60)

7% (2/29)

0% (0/31)

2% (1/60)

aCA,

categorical agreement; mE, minor error; ME, major error; VME, very major error; Repro, reproducibility.
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FIG 2 Ana-CIM zone size reading guide. Representative carbapenemase positive (A, C, and D) and
negative (B) clinical isolates are shown with conﬂuent growth up to the disk (A) or microcolonies
within the zone of inhibition (C and D). Consistent with the Clinical and Laboratory Standards
Institute (CLSI) M100 Ed30, colonies within the zone are read as growth (6 mm). Solid black lines
represent measurement, and measured zone size is listed at the bottom of each panel in millimeters.

Ana-CIM for B. fragilis

Journal of Clinical Microbiology

RESULTS
Pilot study. To verify that the proposed Ana-CIM was robust and reproducible in
different clinical laboratories, a set of 20 B. fragilis isolates with variable carbapenem susceptibility and 3 QC isolates (positive controls, Klebsiella pneumoniae ATCC BAA-1705 and B. fragilis
WIS-ImiR-001; negative control, B. fragilis ATCC 25285) were selected by WU and sent to MC
and NCH sites for Ana-CIM. MC and NCH test sites were blind to the expected results. Among
pilot study isolates (WU01 to WU20), 8 were resistant to ertapenem ($16 m g/mL) by Etest by
both CLSI and EUCAST. Across all sites, QC isolates tested within the expected range per the
CLSI M100 Ed30 Enterobacterales mCIM (see File 1 in the supplemental material). Eighteen
(90%) pilot study test isolates had zone sizes within 2 mm across all sites (Table S2). When
interpreted using CLSI M100 Ed30 mCIM Enterobacterales interpretive criteria (Table 1), categorical agreement (CA) of Ana-CIM for the pilot study isolates was 95% at WU, 95% at MC,
and 75% at NCH. The difference among sites was due to 6 isolates, WU02, WU05, WU07,
WU10, WU16, and WU20, which were susceptible to ertapenem but were interpreted as indeterminate by mCIM criteria at 1 or more sites (Table S2). However, review of discrepant isolates
revealed that all zone sizes were within 3 mm (range, 18 to 21 mm) across all sites (Table S2).
Interpretive criteria for mCIM were therefore not suitable for this assay as B. fragilis isolates that
were phenotypically carbapenem susceptible were interpreted as indeterminate when mCIM
criteria were applied to Ana-CIM testing. As such, we proposed laboratory-developed Ana-CIM
interpretative criteria (Table 1). When lab-developed Ana-CIM interpretive criteria were applied
to pilot study testing, 95% (19/20) concordance in interpretation was observed across the 3
sites, with one indeterminate result at MC. CA compared to ertapenem Etest phenotypic susceptibility was 95% (19/20 isolates) with 1 mE (1/20, 5%). There were no VMEs (0/8) or MEs (0/
12) observed at any sites (Table 2 and Table S2).
Clinical validation study. Having demonstrated that the Ana-CIM could be performed
at multiple sites with greater than 90% concordant results in the pilot study, we undertook
a multicenter clinical validation study. Thirty-ﬁve B. fragilis isolates (C1 to C35) were tested
by Ana-CIM at all three sites. Twelve isolates tested resistant to ertapenem by Etest interpreted by CLSI criteria, while 18 isolates tested resistant using EUCAST breakpoints (Table
S1). MC and NCH sites were blind to phenotypic carbapenem susceptibility status of all isolates. When the proposed Ana-CIM interpretive criteria were applied, concordance was
observed in 94% (33/35 isolates) at all 3 sites (Table 3). MC observed indeterminate results
for C19 and C25, while WU and NCH observed positive Ana-CIM results for both of these isolates. Similar to the pilot study testing, the majority (86%; 30/35) of clinical validation study
isolates had Ana-CIM zones sizes within 2 mm across all sites (Table 3 and Fig. 3). CA of the
Ana-CIM results compared to ertapenem Etest susceptibility result was 86% (30/35) with no
VMEs (0/12) and 10% (2/20) ME and 9% (3/35) mE rates (Table 2). Three isolates (C12, C19,
and C26) tested intermediate by ertapenem Etest when applying CLSI interpretive criteria,
but resistant by EUCAST criteria, which accounted for the 3 mEs. Isolates C24 and C25
accounted for the ME, as both tested susceptible by ertapenem Etest (resistant by agar dilution, resistant to meropenem by Etest and agar dilution) by CLSI guidelines (Tables 2 and 3
and Table S1).
Reproducibility testing. To assess the reproducibility of the Ana-CIM, 5 isolates (R1
to R5; Table S1) as well as the 3 QC isolates were tested using 3 different commercially
available MH agar plates from Hardy, BD, and Remel. Each isolate was tested in triplicate on
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Using CLSI M100 Ed30 interpretive guidelines (14), Ana-CIM results were also compared to ertapenem agar
dilution, meropenem Etest, and meropenem agar dilution susceptibility (see Table S5). The CLSI breakpoints for
meropenem and ertapenem at the time of this study were #4 m g/mL, susceptible; 8 m g/mL, intermediate;
and $16 m g/mL, resistant. Additionally, in a separate, standalone analysis, Ana-CIM testing was also compared to
meropenem and ertapenem susceptibility evaluated with Etest and agar dilution methods interpreted using
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2020 breakpoints (15) (Table 2 and
Table S5). The EUCAST breakpoints for ertapenem and meropenem at the time of this study were #0.5 m g/mL,
susceptible, and .0.5 m g/mL, resistant, and #2 m g/mL, susceptible, and .8 m g/mL, resistant, respectively.
Discrepant analysis. Isolates with discrepant results (difference in Ana-CIM zone sizes of $5 mm
between sites) were subject to discrepant analysis. New isolate stocks were prepared at WU and resent to MC
and NCH. All sites retested new and original isolate stocks. Only 1 isolate was subjected to discrepant analysis
among the sites; this resolved with repeat testing. Thus, results of repeat testing were used for ﬁnal analyses.
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TABLE 3 Ana-CIM clinical study testinga

Isolate
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35

Erta Etest
S
S
R
R
R
S
S
S
R
S
S
I
R
R
S
S
S
R
I
R
S
S
S
S
S
I
S
S
S
R
S
R
R
S
R

Zone size (mm)
18
18
6
6
6
17
18
19
6
18
18
17
6
6
18
19
19
6
6
6
17
19
18
6
6b
6b
18
19
19
6
19
6
6
19
6

MC
Interp Ana-CIM
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Pos
Pos
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Pos
Pos
Neg
Pos

Zone size (mm)
19
18
6
6
6
19
19
19
6
18
19
18
6
6
18
19
18
6
9
6
18
18
18
6
10
6
18
18
18
6
18
6
6
17
6

NCH
Interp Ana-CIM
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Pos
Pos
Neg
Neg
Neg
Pos
Ind
Pos
Neg
Neg
Neg
Pos
Ind
Pos
Neg
Neg
Neg
Pos
Neg
Pos
Pos
Neg
Pos

Zone size (mm)
20
21
6
6
6
21
20
20
6
20
20
21
6
6
20
20
20
6
6
6
19
20
20
6b
6
6b
19
19
18
6
19
6b
6
18
6

Interp Ana-CIM
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Pos
Pos
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Pos
Pos
Neg
Pos

aErta,

ertapenem; Ind, indeterminate; Interp, interpretation; MC, Mayo Clinic; NCH, Nationwide Children’s Hospital; Neg, negative; Pos, positive; WU, Washington University;
S, susceptible; R, resistant; I, intermediate.
bMicrocolonies within zone.

each MH agar on three different days at each site (Fig. 4 and Tables 4 and 5). The mode and
range were reported for each MH agar brand, at each test site, and across all replicates
(Tables 4 and 5). All QC isolates were within the expected range (#8 mm for K. pneumoniae
ATCC BAA-1705 and B. fragilis WIS-ImiR-001, $15 mm for B. fragilis ATCC 25285) with 100%
CA. All measured zone sizes were within 2 mm of the mode for each control isolate (Fig. 4
and Tables 4 and 5). There was 100% categorical agreement across all sites for isolates R1,
R3, and R4 with all observed values within 2 mm between replicates (Fig. 4A, C, and D and
Tables 4 and 5). However, categorical agreement for isolates R2 and R5, which both tested
susceptible by ertapenem Etest CLSI guidelines, was 4% (range, 0 to 4% between sites) and
37% (range, 0 to 59% between sites), respectively. For isolate R2, the majority of readings
resulted in an Ana-CIM zone size of 6 mm with only 3.7% (3/81) of replicates with zone sizes
measuring greater than 5 mm from the mode (6 mm). However, for isolate R5, 50% (41/81)
of replicates had zone sizes measuring greater than 5 mm from the mode (mode, 6 mm;
range, 6 to 18 mm. Isolate R5 zone sizes that were off the mode hovered around the indeterminate and negative interpretations using the proposed Ana-CIM interpretive criteria (Fig. 4E).
While colonies within the zone of inhibition were variably observed at all sites for isolate R5,
isolate R2 consistently displayed microcolonies at NCH (22/27 replicates) only; this was rarely
observed at other sites (WU, 1/27; MC, 0/27). There was no apparent association of microcolonies during Ana-CIM testing of R2 and R5 with speciﬁc MH medium bands (Table 4).
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Agreement of Etest and agar dilution phenotypic susceptibility methods. All B.
fragilis isolates in this study were initially tested by Etest for phenotypic susceptibility
to ertapenem and meropenem. Subsequently, phenotypic susceptibility testing was performed by the gold standard method of agar dilution for both ertapenem and meropenem.
The methods were largely concordant for both ertapenem (92% CA) and meropenem (98%
CA) by CLSI standards (Table S3). Furthermore, Ana-CIM performance compared to Etest
and agar dilution susceptibility by CLSI breakpoints was highly concordant for both ertapenem (87% CA Etest and 93% CA agar dilution) and meropenem (98% CA Etest and 97% CA
agar dilution) (Table S4). As such, ertapenem Etest was maintained as the reference method
for Ana-CIM performance assessment. Overall, Ana-CIM had 87% or greater CA compared to
either meropenem or ertapenem AST tested by either Etest or agar dilution and interpreted
by CLSI or EUCAST breakpoints (Table 2 and Tables S4 and S5).
We reviewed isolates with carbapenem categorical results that were discordant between
CLSI and EUCAST guidelines. In this study, 8 isolates (13%) by ertapenem Etest exhibited
MICs in this range of .0.5 m g/mL (EUCAST ertapenem-resistant breakpoint) and ,16 m g/mL
(CLSI ertapenem-resistant breakpoint) (Table S6). Six of these 8 isolates were tested in the clinical study, where 2 (C12 and C23) tested negative for carbapenemase production by Ana-CIM
at all sites and C19 tested positive at 2/3 sites and indeterminate at one site. The remaining 3
isolates (C24, C25, and C26) tested positive across all 3 sites with 2 noted to have microcolonies. Isolates R2 and R5 tested positive by Ana-CIM, both with a mode of 6 mm; microcolonies
were noted for both isolates. None of the 8 isolates had an IS element detected by PCR,
though 6 of the 8 isolates had a CﬁA callout by MALDI-ToF MS (Table S1).
DISCUSSION
With carbapenem resistance on the rise in B. fragilis, rapid methods readily adaptable to
clinical laboratories will be needed to detect resistance and decrease the likelihood of carbapenem treatment failure. PCR-based methods that detect the carbapenemase gene cﬁA and
activating upstream insertion sequences are not practical in most clinical microbiology laboratory settings. Double-ended Etest strips of meropenem or imipenem with or without
EDTA have been proposed; however, preliminary analyses indicate that sensitivity is highly
variable based on the carbapenem utilized and the resistance level of the isolates tested. For
April 2022 Volume 60 Issue 4

10.1128/jcm.02188-21

7

Downloaded from https://journals.asm.org/journal/jcm on 07 June 2022 by 128.252.174.220.

FIG 3 Ana-CIM zone size distribution of clinical isolates tested at all sites. Zone sizes for Ana-CIM
testing for each clinical validation study isolate are shown. Results for Nationwide Children’s Hospital (NCH)
(orange triangles), Mayo Clinic (MC) (green squares), and Washington University School of Medicine (WU)
(blue circles) are shown. The isolates labeled in red along the x axis tested resistant by the ertapenem Etest,
while the isolates in black tested susceptible. Lab-developed Ana-CIM interpretive criteria are shown as red
solid lines, and CLSI mCIM interpretive criteria for Enterobacterales are shown in dashed gray lines.

Journal of Clinical Microbiology

FIG 4 Distribution of Ana-CIM zone sizes for reproducibility study isolates. Histograms include all 81 Ana-CIM zone-ofinhibition measurements for each of the 5 test isolates (A to E) and the quality control (QC) isolates (F to H) in the reproducibility
study. Each isolate was tested in triplicate on 3 different commercially available Mueller-Hinton agar plates on 3 different days at the
3 clinical laboratories (27 zone measurements from each site for each of the isolates for a total of 81 replicates for each isolate).

meropenem 6 EDTA and imipenem 6 EDTA Etests, sensitivity of 87% and 27%, respectively, has been reported for detection of cﬁA-positive B. fragilis isolates (18).
More recently, MALDI-ToF-based methods for carbapenemase detection and conﬁrmation
have been proposed using MALDI subtyping and MBT-STAR-Carba (Bruker Daltonik, Germany)
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TABLE 4 Ana-CIM reproducibility testing by medium manufacturer and testing sitea
Mode (range) by manufacturer and testing site:
Hardy
c

Isolate
R1
R2
R3
R4
R5
Kp pos control
Bf pos control
Bf neg control

WU
19 (18–20)
6 (6)
19 (18–20)
6 (6)
15 (7–16)
6 (6)
6 (6)
19 (18–20)

Remel
MC
18 (17–19)
6 (6)
18 (17–19)
6 (6)
6b (6–14)
6 (6)
6 (6)
18 (17–19)

NCH
19 (18–20)
6b (6–16)
19 (18–20)
6 (6)
16b (6–17)
6 (6)
6 (6)
20 (18–20)

BD

WU
18 (18–21)
6 (6)
19 (18–20)
6 (6)
6b (6–16)
6 (6)
6 (6)
18 (18–20)

MC
18 (17–19)
6 (6)
18 (17–19)
6 (6)
6b (6–14)
6 (6)
6 (6)
18 (17–18)

NCH
18 (18–19)
6b (6)
19 (18–20)
6 (6)
17b (6–18)
6 (6)
6 (6)
18 (18–20)

WU
18 (17–20)
6 (6)
18 (18–20)
6 (6)
13 (13–15)
6 (6)
6 (6)
19 (19–20)

MC
19 (17–19)
6 (6)
19 (18–19)
6 (6)
6b (6)
6 (6)
6 (6)
19 (17–20)

NCH
19 (19–20)
6b (6)
19 (19–20)
6 (6)
6b (6–17)
6 (6)
6 (6)
19 (19–20)

aKp

pos control, K. pneumoniae ATCC BAA-1705; Bf pos control, B. fragilis WIS-ImiR-001; Bf neg control, B. fragilis ATCC 25285.
within zone.
cEach isolate was tested a total of 81 times (3 replicates per day on 3 different testing days at 3 different sites).

(19). Using the MBT-STAR-Carba kit that measures imipenem hydrolysis following organism
plus antibiotic incubation for up to 60 min, Cordovana and colleagues reported 100% sensitivity for detection of cﬁA-positive B. fragilis isolates among a collection of 70 cﬁA-positive and 33
cﬁA-negative isolates (19). In contrast, they reported that off-label anaerobic adaptations of
Carba NP and disk diffusion synergy tests had sensitivity of only 20.7% and 79.3%, respectively,
and preferentially detected carbapenemase production in isolates with high-level carbapenem
resistance (19). While the MBT-STAR-Carba appears promising, this test requires additional
reagents and speciﬁc instrumentation (Microﬂex LT mass spectrometer) and software and
is not widely utilized in clinical microbiology laboratories despite excellent performance
characteristics.
In this study, we have described the Ana-CIM, a modiﬁcation of the widely utilized carbapenem inactivation method (CIM) adapted for detection of carbapenemase production in B.
fragilis isolates. There are two main modiﬁcations of the mCIM assay for the Ana-CIM assay.
The ﬁrst change is the broth medium utilized for the incubation step. For the mCIM assay,
tryptic soy broth (TSB) is used; however, the Ana-CIM assay speciﬁcally utilizes Brucella broth,
which is formulated for recovery of fastidious and anaerobic organisms such as B. fragilis. The
second modiﬁcation is the anaerobic incubation conditions immediately following the isolate
inoculation into the broth medium with the meropenem disk. The mCIM mixture is incubated
for 4 h at 35°C in ambient air, which is sufﬁcient for Enterobacterales that replicate quickly in a
nutrient-rich broth. During the development of the Ana-CIM, both 6- and 24-h anaerobic incubations were tested and there was no difference in zone sizes between the two incubation
times. After the anaerobic incubation step, the Ana-CIM and mCIM are identical.
The Ana-CIM exhibited 87% (52/60) CA with ertapenem Etest results across all sites for the
60 isolates tested in the pilot, clinical, and reproducibility studies with no VME, 11% (4/36) ME,

TABLE 5 Ana-CIM reproducibility testing by number of tests with zone size off the modea

Isolateb
R1
R2
R3
R4
R5
Kp pos control
Bf pos control
Bf neg control

Mode for all
tests (mm)
19
6
19
6
6
6
6
19

Total

No. of tests with zone size (mm) off the mode
<25

0

25

0

24

0

23

0

22
4

21
29

2

27

3

29

0
37
78
41
81
39
81
81
30

9

85

468

+1
10

41

+2
1

+3

+4

+5

>+5
3

11
1

41

19
1

0

0

0

44

aKp

pos control, K. pneumoniae ATCC BAA-1705; Bf pos control, B. fragilis WIS-ImiR-001; Bf neg control, B. fragilis ATCC 25285.
bEach isolate was tested a total of 81 times (3 replicates per day on 3 different testing days at 3 different sites).
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and 7% (4/60) mE. In addition to high CA compared to phenotypic susceptibility results, we
also report that the Ana-CIM is reproducible across test sites and with 3 different brands of
MH medium. While 3/5 reproducibility study isolates demonstrated 100% CA across all sites,
some variability was observed with isolates R2 and R5. Interestingly, both of these isolates
tested susceptible to ertapenem and meropenem when CLSI breakpoints were applied but
were interpreted as ertapenem resistant or meropenem nonsusceptible using
EUCAST breakpoints (see Table S1 in the supplemental material). Ana-CIM testing
was positive for carbapenemase production in 96% (78/81) of instances for R2 and
49% (40/81) of instances for R5. Microcolonies were observed at multiple testing sites
and on multiple medium types for both R2 and R5, suggesting that they are harboring a carbapenemase and may display a resistant phenotype (Table 4).
The variability in Ana-CIM results observed with R2 and R5 may be due to elevated
but relatively low carbapenem MICs that may be interpreted as susceptible or resistant
depending on the interpretive guideline applied. In addition to R2 and R5, 6 additional
clinical isolates had ertapenem Etest MICs with discordant interpretations by CLSI versus
EUCAST, of which 5/6 had consensus Ana-CIM interpretations across all sites (Table S6).
The signiﬁcance of isolates with carbapenem MICs in this range is unclear, as they are not
commonly reported (6, 20).
The presence of microcolonies within the zone of inhibition of select isolates may also
confound Ana-CIM interpretation. Colonies of the indicator strain, E. coli ATCC 25922,
within the zone were interpreted as growth consistent with the CLSI guidance on interpretation of Enterobacterales and Pseudomonas aeruginosa mCIM (Fig. 2). Overall, microcolonies within the zone were infrequent, occurring in 6/60 of the isolates evaluated, but were
more often observed in isolates with carbapenem MICs ranging from 2 to .32 m g/mL.
Additional studies interrogating the genetic mechanism of resistance in isolates with intermediate carbapenem MICs or microcolonies within zones of inhibition by the Ana-CIM are
needed to corroborate these ﬁndings.
Interestingly, molecular cﬁA and IS detection was largely concordant with phenotypic resistance. All 60 study isolates had cﬁA detected by PCR. Nineteen isolates had cﬁA and IS
detected via PCR, all of which were also phenotypically carbapenem resistant and Ana-CIM
positive. Forty-one were cﬁA positive but IS negative; of which 10 (24%) were resistant to either meropenem or ertapenem when evaluated by either CLSI or EUCAST breakpoints
(Table S1). Eighty percent (8/10) of these isolates were Ana-CIM positive, further indicating
that cﬁA and IS PCR alone are insufﬁcient to identify carbapenemase production in B. fragilis.
Of these 8 isolates, 6 had a callout for CﬁA by the Bruker Biotyper, suggesting that these isolates may harbor an IS that is not detected by the PCR assay.
This study has several strengths and weaknesses. Notable strengths include the inclusion
of clinical B. fragilis isolates from multiple study sites, with a large proportion of resistant strains
for analysis. Additionally, three different brands of MH agar were tested in three clinical microbiology laboratories in order to assess reproducibility. However, the overall study sample size
is limited. Another limitation of this study is that the assay has not been evaluated for other
Bacteroides species and thus can be deployed only in laboratory settings where species-level
identiﬁcation is available.
We demonstrated that this method has favorable performance characteristics in the hands
of multiple test sites and reagent manufacturers and can be readily adapted by clinical microbiology laboratories with no additional instrumentation or software. These initial ﬁndings indicate the Ana-CIM can be an effective method for detection of carbapenemase production in
B. fragilis isolates. For laboratories capable of anaerobic isolation, the Ana-CIM is a simple and
low-cost addition to the test menu that can be used to conﬁrm carbapenemase production in
B. fragilis.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.4 MB.
SUPPLEMENTAL FILE 2, PDF ﬁle, 0.4 MB.
April 2022 Volume 60 Issue 4

10.1128/jcm.02188-21

10

Downloaded from https://journals.asm.org/journal/jcm on 07 June 2022 by 128.252.174.220.

Ana-CIM for B. fragilis

Ana-CIM for B. fragilis

Journal of Clinical Microbiology

ACKNOWLEDGMENTS
We thank Nathan Ledeboer of the Medical College of Wisconsin for providing the B.
fragilis WIS-ImiR-001 positive-control isolate and Katie Riese of the Mayo Clinic for
technical assistance with this study.

1. Nguyen MH, Yu VL, Morris AJ, McDermott L, Wagener MW, Harrell L,
Snydman DR. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: ﬁndings of a multicenter prospective observational
trial. Clin Infect Dis 30:870–876. https://doi.org/10.1086/313805.
2. Boente RF, Ferreira LQ, Falcão LS, Miranda KR, Guimarães PL, Santos-Filho
J, Vieira JM, Barroso DE, Emond JP, Ferreira EO, Paula GR, Domingues RM.
2010. Detection of resistance genes and susceptibility patterns in Bacteroides and Parabacteroides strains. Anaerobe 16:190–194. https://doi.org/
10.1016/j.anaerobe.2010.02.003.
3. Snydman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins
SG, Newton D, Patel R, Hecht DW. 2017. Trends in antimicrobial resistance
among Bacteroides species and Parabacteroides species in the United
States from 2010–2012 with comparison to 2008–2009. Anaerobe 43:
21–26. https://doi.org/10.1016/j.anaerobe.2016.11.003.
4. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L,
Jenkins S, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan
AM, Hecht DW. 2011. Update on resistance of Bacteroides fragilis group and
related species with special attention to carbapenems 2006–2009. Anaerobe
17:147–151. https://doi.org/10.1016/j.anaerobe.2011.05.014.
5. Hawser SP, Hackel M, Hoban DJ. 2010. Antibiotic susceptibility proﬁles of
European Bacteroides fragilis with reduced carbapenem susceptibility. J
Antimicrob Chemother 65:803–804. https://doi.org/10.1093/jac/dkq016.
6. Fernández-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di
Martino A, Rossetti A, Rollet R, Carloni G, Bianchini H, Cejas D, Radice M,
Gutkind G, Anaerobe Surveillance Team. 2012. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina. Antimicrob Agents Chemother 56:
1309–1314. https://doi.org/10.1128/AAC.05622-11.
7. Edwards R, Read PN. 2000. Expression of the carbapenemase gene (cﬁA)
in Bacteroides fragilis. J Antimicrob Chemother 46:1009–1012. https://doi
.org/10.1093/jac/46.6.1009.
8. Ho PL, Yau CY, Ho LY, Chen JHK, Lai ELY, Lo SWU, Tse CWS, Chow KH.
2017. Rapid detection of cﬁA metallo- b -lactamase-producing Bacteroides
fragilis by the combination of MALDI-TOF MS and CarbaNP. J Clin Pathol
70:868–873. https://doi.org/10.1136/jclinpath-2017-204335.
9. Schwensen SA, Acar Z, Sydenham TV, Johansson Å, Justesen US. 2017. Phenotypic detection of the cﬁA metallo-b -lactamase in Bacteroides fragilis with the
meropenem-EDTA double-ended Etest and the ROSCO KPC/MBL Conﬁrm kit. J
Antimicrob Chemother 72:437–440. https://doi.org/10.1093/jac/dkw436.
10. Wybo I, De Bel A, Soetens O, Echahidi F, Vandoorslaer K, Van Cauwenbergh
M, Piérard D. 2011. Differentiation of cﬁA-negative and cﬁA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization–time of

April 2022 Volume 60 Issue 4

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

ﬂight mass spectrometry. J Clin Microbiol 49:1961–1964. https://doi.org/10
.1128/JCM.02321-10.
Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso
WB, Bobenchik AM, Lockett ZC, Charnot-Katsikas A, Ferraro MJ, Thomson
RB, Jenkins SG, Limbago BM, Das S. 2017. Modiﬁed carbapenem inactivation
method for phenotypic detection of carbapenemase production among
Enterobacteriaceae. J Clin Microbiol 55:2321–2333. https://doi.org/10.1128/
JCM.00193-17.
Wallace MJ, Jean S, Wallace MA, Burnham CD, Dantas G. 2022. Comparative genomics of Bacteroides fragilis group isolates reveals species-dependent resistance mechanisms and validates clinical tools for resistance
prediction. mBio 13:e03603-21. https://doi.org/10.1128/mbio.03603-21.
Clinical and Laboratory Standards Institute. 2018. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
Clinical and Laboratory Standards Institute. 2020. Performance standards
for antimicrobial susceptibility testing, 30th ed. Clinical and Laboratory
Standards Institute, Wayne, PA.
The European Committee on Antimicrobial Susceptibility Testing. 2020.
Breakpoint tables for interpretation of MICs and zone diameters. Version
10.0. http://www.eucast.org.
Sóki J, Fodor E, Hecht DW, Edwards R, Rotimi VO, Kerekes I, Urbán E, Nagy
E. 2004. Molecular characterization of imipenem-resistant, cﬁA-positive
Bacteroides fragilis isolates from the USA, Hungary and Kuwait. J Med
Microbiol 53:413–419. https://doi.org/10.1099/jmm.0.05452-0.
Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ,
Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold
SM, Rosenblatt JE, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007).
Clin Infect Dis 50(Suppl 1):S26–S33. https://doi.org/10.1086/647940.
Bogaerts P, Engelhardt A, Berhin C, Bylund L, Ho P, Yusof A, Glupczynski
Y. 2008. Evaluation of a new meropenem-EDTA double-ended Etest strip
for the detection of the cﬁA metallo-beta-lactamase gene in clinical isolates of Bacteroides fragilis. Clin Microbiol Infect 14:973–977. https://doi
.org/10.1111/j.1469-0691.2008.02065.x.
Cordovana M, Kostrzewa M, Sóki J, Witt E, Ambretti S, Pranada AB. 2018.
Bacteroides fragilis: a whole MALDI-based workﬂow from identiﬁcation to
conﬁrmation of carbapenemase production for routine laboratories.
Anaerobe 54:246–253. https://doi.org/10.1016/j.anaerobe.2018.04.004.
Gao Q, Wu S, Xu T, Zhao X, Huang H, Hu F. 2019. Emergence of carbapenem resistance in Bacteroides fragilis in China. Int J Antimicrob Agents
53:859–863. https://doi.org/10.1016/j.ijantimicag.2019.02.017.

10.1128/jcm.02188-21

11

Downloaded from https://journals.asm.org/journal/jcm on 07 June 2022 by 128.252.174.220.

REFERENCES

